Aileron Raises $10 Million

Cambridge-based biopharmaceutical company Aileron Therapeutics, which is developing peptide drugs for the treatment of cancer and other diseases, has raised $10 million in a private placement of preferred stock, the company announced today. Apple Tree Partners and the Novartis Venture Fund led the round.

Bob is Xconomy's founder and chairman. You can email him at bbuderi@xconomy.com. Follow @bbuderi

Trending on Xconomy